Although the clinical validity of Ki-67 remains uncertain, Ki-67 values are often considered when deciding on suitable adjuvant chemotherapy for patients with ER-positive, HER2-negative breast cancer [22–24]. This evidence concerns the gene ERBB2 and breast carcinoma.